江苏集萃药康生物科技股份有限公司关于以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a share repurchase plan using its own funds and a special loan for stock repurchase, with a total amount between RMB 22 million and RMB 40 million, and a maximum price of RMB 18 per share, within a 12-month period [1] Group 2 - As of July 31, 2025, the company has repurchased a total of 1,067,387 shares, accounting for 0.2603% of the total share capital of 410 million shares, with a total expenditure of RMB 13,914,990.75 [2] Group 3 - The share repurchase is in compliance with relevant laws and regulations [3] Group 4 - The company will make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [4]